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ORIGINAL ARTICLECurrent Versus Lifetime Depression, APOE
Variation, and Their Interaction on Cognitive
Performance in Younger and Older Adults
Michelle Luciano, PhD, Ana Maria Fernández Pujals, MSc, Riccardo E. Marioni, PhD,
ArchieCampbell,MA,CarolineHayward, PhD,Donald J.MacIntyre,MBchB,David J. Porteous, PhD,
AndrewM.McIntosh, MD, and Ian J. Deary, PhD, for the Generation Scotland InvestigatorsABSTRACT
Objective:An interaction effect of depressive symptoms and APOE e4 allele status on cognitive decline has been shown in
old age: e4 allele carriers with more depressive symptoms have faster cognitive decline than those with either depression or
the e4 allele. We test this interaction effect on four cognitive domains, using a clinical depressionmeasure comparing current
versus lifetime depression.
Methods: 14,379 individuals aged 18 to 59 years, and 3944 individuals aged 60 to 94 years from the Generation Scotland:
Scottish Family Health Study participated. Linear-mixed models—accounting for participant relatedness and demographic
and health indices—tested for effects of depression and APOE on cognitive abilities.
Results: There was no interaction between depression and APOE on cognition (p > .05). Current depression was associated
with poorer speed (in both groups) and memory (18- to 59-year-olds); differences ranged from 0.01 to 0.03 standard devi-
ation [SD]. For lifetime depression, cognitive performance was lower for digit symbol in younger adults, but higher for vo-
cabulary in both younger (0.03 SD) and older (0.05 SD) adults. A negative effect of the APOE e4 allele on speed and
memory was found in the group 60 years and older (effect sizes of 0.04 SD).
Conclusions: The absence of a depression by APOE interaction on cognitive abilities suggests that these synergistic effects
only operate at the level of cognitive decline. This implies that it is those biological pathways especially affected by aging
that become compromised further by the combined presence of depression and APOE e4 in an individual.
Keywords: Structured Clinical Interview for DSM-IV depression, general health questionnaire, processing speed, memory,
verbal ability, apolipoprotein E.AD= Alzheimer's disease,APOE = apolipoprotein E,GHQ =Gen-
eral Health Questionnaire, GS:SFHS = Generation Scotland: Scot-
tish Family Health StudyINTRODUCTION
Depression and variation in the apolipoprotein E(APOE) gene are each associated with cognitive
ability. The presence of depression/depressive symptoms
is related to poorer cognitive function (1,2). Carriers of
the APOE e4 allele show worse cognitive test perfor-
mance (3) and increased cognitive decline over time
(4–6). There is mounting evidence to suggest that theSupplemental Content
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Depression by APOE Interaction on Cognitionpresent study has a very large sample and measures of clin-
ically derived depression and current psychological distress
symptoms. Longitudinal measurements are not available,
but the wide age range enables testing of interaction effects
in younger and older age groups. The comparison of cur-
rent versus lifetime depression could provide insight into
any enduring effects of depression on cognitive abilities.
Cognitive decrements in a number of different domains
have been documented in both young and old people with
clinical depression (9–11). A meta-analysis of 14 studies
showed that severity of depression was related especially
to episodic memory, executive function, and processing
speed domains (1). In a population-based study of 2486
people 60 years and older diagnosed as having Interna-
tional Classification of Diseases, 10th Revision unipolar de-
pression, moderate/severe depression was related to slower
processing speed and poorer attention, executive function,
verbal fluency, episodic memory, and vocabulary (12). Ef-
fects were not observed for short-term memory, general
knowledge, or spatial ability. Observations of cognitive
functioning in clinically depressed samples (mostly middle
aged or older) in remission (13–15) suggest that cognitive
decrements are not simply a state-like feature of the current
depressive episode, but rather a more enduring feature.
The APOE e4 variant increases risk for late-onset Alz-
heimer's disease (AD) in a dose-dependent manner (16).
A meta-analysis of up to 56 studies has further shown a
negative relationship with global cognitive function, epi-
sodic memory, executive function, and perceptual speed
in nondemented, mostly older (>60 years), adults (3). The
effect sizes were small, with the explained variance ac-
counting for, at most, half of a percent. Some argue that
such associations reflect incipient AD (e.g., Ref. (17)). A
magnetic resonance imaging study (18) comparing AD
symptom–free APOE e4 carriers and noncarriers showed
smaller hippocampal volume in carriers, especially those
who were younger than 65 years. A follow-up of this sample
could test whether smaller hippocampal volume is associated
only with AD progression and inform the debate on whether
incipient AD drives the APOE findings in normal cognitive
aging. Hippocampal atrophy is also a feature of depression
in the older people; depressed individuals (≥60 years old)
showed larger atrophy in the left hippocampus, accompanied
by greater cognitive decline, than did the nondepressed
elders (19). In an elderly Chinese population, the presence
of depression and the APOE e4 allele was related to greater
disruption of the hippocampal functional connectivity net-
work projecting to the bilateral dorsal anterior cingulate cor-
tex, and the amount of disruption was associated with poorer
cognitive functioning (20). The potential of synergistic
effects of depression and APOE has also been reported in
terms of cognitive decline.
In a prospective longitudinal study of community-
dwelling adults 65 years and older (n = 1992), the effectsPsychosomatic Medicine, V 77 • 480-492 481
Copyright © 2015 by the American Psychosomatic Society.of depressive symptoms (Center for Epidemiological Stud-
ies Depression Scale) and APOE e4 allele status on global
cognitive change over a 6-year period were measured (7).
Main effects of depression and APOE e4 allele status on
cognitive decline were confirmed; moreover, an interaction
effect showed that carriers of the e4 allele with more depres-
sive symptoms at baseline had the greatest cognitive de-
cline, and this was consistent across all ages. In older
Chinese adults (n = 1487), an interaction of depressive
symptoms and APOEwas found despite an absence ofmain
effects: depressed APOE e4 carriers at baseline showed a
40% reduction in their cognitive ability over a 1- to 2-year
period compared with a 28.6% reduction in nondepressed
APOE e4 carriers (21). The largest prospective study
(n = 4150) of community-dwelling older adults (≥65 years)
followed up to six times every 3 years confirmed an interac-
tion between depressive symptoms (Center for Epidemio-
logical Studies Depression Scale) and APOE on cognitive
decline over time (8). They evaluated the effect on a general
cognitive ability factor. Each extra depressive symptom in-
creased cognitive decline by 0.002 units per year for non-
carriers of the e4 allele versus a 0.005-unit increase for e4
carriers. These studies provide strong evidence for a height-
ened effect of depression and APOE e4 status together on
cognitive decline in old age, but their small size precluded
investigation of genotypic effects. One might, for example,
expect more pronounced effects for e4 homozygote car-
riers, who are at greater risk of AD.
The size of the present study allows for an investigation
of a number of genotypic effects. In addition, clinical phe-
notyping enables dissociation of individuals with depres-
sive illness into those with and without current clinically
significant depression at the time of cognitive testing. Cur-
rent depression might be a direct cause of poorer cognition
due to associated reductions in motivation and attention that
characterize an episode of depression. However, if such ef-
fects remain in people with a history of depression who are
not currently depressed, then this could indicate a trait-like
causal mechanism (e.g., brain structural differences). In the
absence of longitudinal data, the present study compares re-
sults for groups of younger (18–59 years) versus older
(60–94 years) adults, which captures the bimodal age distri-
bution of incidence rate for mood disorders (22). This age
split was based on age ranges reported in previous studies
of the elderly (12) and also on the distribution of cognitive
data in the Generation Scotland: Scottish Family Health
Study (GS:SFHS), which showed changes in mean cogni-
tion around 60 years (23). If the depression and APOE e4
interaction effect is only related to cognitive decline, then
this might be observable (or of larger effect) in the older
age group, whose cognitive abilities will reflect increased
variation due to aging. The interaction effect will also be con-
sidered separately for four cognitive domains (processing
speed, executive function, verbal ability, verbal declarativeJune 2015
 Unauthorized reproduction of this article is prohibited.
ORIGINAL ARTICLEmemory) given that both depression and APOE have shown
differential effects across cognitive domains.METHODS
The sample were from Generation Scotland: the Scottish Family Health
Study (GS:SFHS), a large population and family-based study that recruited
around 24,000 Scottish participants between the years 2006 and 2011. Fur-
ther information about sample recruitment and descriptive aspects of this
study can be found in Smith et al. (24) (www.generationscotland.org/).
Briefly, a sample of probands aged between 35 and 65 years (n = 7953)
who were registered with general medical practitioners were invited to par-
ticipate. No selective sampling for specific medical conditions was under-
taken. These probands then asked their relatives to participate in the
study resulting in a final GS:SFHS sample with an extended age range of
18 and 99 years. The present study includes those families who had APOE
genotyping and the relevant complete depression, cognitive ability, and de-
mographic and health data (n = 18,329). Twenty-eight individuals with
AD were excluded. Two subgroups were defined: a younger group (18–
59 years) including 6057 families, of which 2168 were single individuals,
and an older group (60–94 years) comprising 2589 families, 1644 of whom
were singletons. The median number of years of education reported by
study participants was slightly higher in the 18- to 59-year-old group
(14–15 years) compared with the 60- to 94-year-old group (12–13 years).
GS:SFHS ethical approval was granted by the NHS Tayside Committee
on Medical Research Ethics (REC Reference Number: 05/S1401/89). Re-
search Tissue Bank status was approved by the Tayside Committee on
Medical Research Ethics (REC Reference Number: 10/S1402/20), en-
abling generic ethical approval for medical research purposes.
Genotyping
Two single nucleotide polymorphisms, rs7412 and rs429358, were typed to
define APOE allele status. Taqman technology (5-μl volume assays) was
used for genotyping and performed at the Wellcome Trust Clinical Re-
search Facility Genetics Core, Edinburgh, where the DNA stores from
GS:SFHS participants were contained (25).
Measured Traits
Current and lifetime depression was measured by trained researchers by
using the Structured Clinical Interview for DSM-IV disorders; those ini-
tially screening positive for a history of emotional or psychiatric problems
(21.7%) continued the mood disorder–focused interview. Eighty-eight
percent completed the interview. Current psychological distress was also
measured in the full sample by using the 28-item General Health Ques-
tionnaire (GHQ) (26), which measures somatic symptoms, anxiety and
insomnia, social dysfunction, and severe depression. Cognitive ability
in four domains—perceptual speed, verbal declarative memory, execu-
tive function, and vocabulary—was measured by well-validated and re-
liable psychometric tests. These included the Wechsler Digit Symbol
Substitution Test (speed) (27); Wechsler Logical Memory Test (sum
of immediate and delayed recall of one paragraph; memory) (28); the
phonemic Verbal Fluency Test using the letters C, F, and L, each for
1 minute (executive function) (29); and the Mill Hill Vocabulary Scale
combining junior and senior synonyms (vocabulary) (30).
Self-reported information of a medical/health-related nature was col-
lected by questionnaire, and these were data treated as potential con-
founders in the present study. The variables included smoking status
(never, previous, current), alcohol consumption (units in the past week),
physical activity (frequency per week of vigorous activity/physical activity
of >20-min duration in leisure time), total number of chronic health condi-
tions (heart disease, stroke, high blood pressure, diabetes, Parkinson disease,
cancer [breast, bowel, lung, prostate], hip fracture, arthritis [osteomatoid,Psychosomatic Medicine, V 77 • 480-492 482
Copyright © 2015 by the American Psychosomatic Society.rheumatoid], asthma). Relevant clinically attained measures included height
and weight, used to calculate body mass index.
Statistical Analyses
Linear mixed-effects models including depression and APOE and their in-
teraction were fitted to each cognitive measure and included main effects
for age, sex, and potential confounding variables (covariates were mean
centered). Four sets ofmixedmodels were run so that (1) current depression
versus (2) lifetime depression effects could be compared and, similarly (3),
APOE e4 status (present/absent) versus (4) APOE genotype (e2e2, e2e3,
e2e4, e3e4, e4e4, and e3e3 as the reference group). Further analyses were
performed replacing depression status with continuous scores from the
GHQ; these results were expected to mimic those of current depression
but with the advantage of having increased statistical power. All analyses
were performed separately for younger (<60 years) and older (≥60 years)
groups, with the expectation that the depression by APOE interaction
effect would be stronger in the older group. Relatedness between indi-
viduals was based on reported pedigree information and used to fit a
random factor that would account for nonindependence between indi-
viduals. The “asreml” library within the “R” statistical software pack-
age was used for analysis (31,32).
RESULTS
Descriptive
In the 18- to 59-year-old group, the number of Structured
Clinical Interview for DSM-IV disorders diagnoses was
as follows: 1053 with single-episode depression (7.3%),
1006 with recurrent depression (7%), and 62 instances of
bipolar disorder (0.4%). In the 60- to 94-year-old group,
there were 181 with single-episode depression (4.6%),
193 with recurrent depression (4.9%), and 6 cases of bipolar
disorder (0.1%). Because previous studies of depressive
symptoms cannot differentiate between unipolar and bipo-
lar states, bipolar cases were included in the main analysis
of depression, but the data were also reanalyzed excluding
bipolar cases. The sample size of each of the depression
by APOE groups by age cohort is shown in Table 1. In
the 60- to 94-year-old group, there were too few people with
current depression to enable reliable analysis of the depres-
sion by APOE interaction effect for this trait. Descriptive
statistics for the 18- to 59-year-old and 60- to 94-year-old
groups are shown in Table 2. χ2 Tests showed that depres-
sion status differed between younger and older groups (cur-
rent depression: χ2 = 31.92, p < .00001; lifetime depression:
χ2 = 20.74, p < .00001), with the 18- to 59-year-old group
being more depressed (3% of sample currently depressed
versus 1% in the older group, 12.3% of sample with life-
time depression versus 9.6% in the older group). There
was no difference in the distribution of APOE e4 allele status
(χ2 = 1.96, p = .16) between groups and no association be-
tween APOE e4 status and depression (current or lifetime)/
psychological distress symptoms within groups (p > .05).
Distributions of the dependent variables were screened
for normality, with outlying scores (0 values for verbal flu-
ency [n = 4], digit symbol [n = 7], and logical memory
[n = 2], and values <9 for vocabulary [n = 7]) excluded fromJune 2015
 Unauthorized reproduction of this article is prohibited.
TABLE 1. Sample Size of Differing Depression (Current, Lifetime) by APOE (e4 Presence, Genotype) Groups for
Adults Aged 18–59 and 60–94 Years
Adults Aged 18–59 y Adults Aged 60–94 y
Current Depression Lifetime Depression Current Depression Lifetime Depression
Yes
(n = 406)
No
(n = 13,973)
Yes
(n = 1715)
No
(n = 12,258)
Yes
(n = 49)
No
(n = 3895)
Yes
(n = 331)
No
(n = 3564)
e4 presence
−e4 299 10,051 1255 8796 38 2845 234 2611
+e4 107 3922 460 3462 11 1050 97 953
Genotype
e2e2 3 89 15 74 1 19 3 16
e2e3 47 1621 196 1425 6 494 31 463
e3e3 249 8341 1044 7297 31 2332 200 2132
e2e4 8 303 38 265 3 98 8 90
e3e4 91 3262 379 2883 7 863 82 781
e4e4 8 357 43 314 1 89 7 82
APOE = apolipoprotein E.
Depression by APOE Interaction on Cognitionanalysis. All cognitive variables were normally distributed.
Where significant (see Table S1, Supplemental Digital Con-
tent, http://links.lww.com/PSYMED/A213), total chronic
diseases, body mass index, and smoking status (scored in
the direction of currently smoke) were negatively associated
with cognitive performance, whereas physical activity and
alcohol intake were positively associated with cognitive per-
formance. Men performed worse than did women on all
tests, except vocabulary, in which they scored higher. Youn-
ger age was associated with better performance on digit
symbol and logical memory. Age effects on verbal flu-
ency were opposite in younger and older groups: age
was positively associated in the 18- to 59-year-old group,
but negatively in the 60- to 94-year-old group. A positive
association between age and vocabulary was also ob-
served in the 18- to 59-year-old group.
Depression and APOE Effects
The results of linear-mixed models which tested the main
and interaction effects of depression and APOE e4 status
on the different cognitive domains are shown in Table 3.
No significant interaction effects were present for either co-
hort. In the 18- to 59-year-old group, current depression
main effects were found for digit symbol (0.03 standard de-
viation [SD] lower) and logical memory (0.02 SD lower),
and lifetime depression main effects were found for digit
symbol (0.02 SD lower), verbal fluency (0.03 SD higher),
and vocabulary (0.03 SD higher). In the 60- to 94-year-
old group, a current depression main effect was similarly
found for digit symbol (0.01 SD lower), with lifetime de-
pression associated with vocabulary (0.05 SD higher).
The direction of these effects was consistent across agePsychosomatic Medicine, V 77 • 480-492 483
Copyright © 2015 by the American Psychosomatic Society.groups: depression related to poorer digit symbol and logi-
cal memory test performance, but positively to verbal flu-
ency and vocabulary. Main effects of APOE e4 presence
were observed for verbal fluency in both age groups (e4 al-
lele associated with better performance) and for digit sym-
bol and logical memory in the 60- to 94-year-old group
(e4 allele associated with worse performance). Results of
modeling APOE genotype are shown in Table 4. No inter-
action effects were observed for those genotype groups in
which there was sufficient sample size to test the interac-
tion. Genotypic main effects revealed better performance
of APOE e3e4 genotype carriers for verbal fluency in the
18- to 59-year-old group. In the 60- to 94-year-old group,
APOE e3e4 and e4e4 genotype groups showed worse per-
formance in digit symbol and logical memory, whereas
the APOE e4e4 genotype group demonstrated better perfor-
mance on verbal fluency. Themain effects of depression are
more reliable (smaller standard errors) in the APOE e4 sta-
tus analysis, so are not highlighted for the APOE genotypic
analyses.
Results of the GHQ (Table 5) mimicked those of current
depression in the APOE genotypic analysis of the adults
aged 18 to 59 years and in the APOE e4 status analysis of
the adults aged 60 to 94 years for all cognitive measures.
In the 18- to 59-year-old group analysis of APOE e4 status,
two measures showed deviation from the current depres-
sion results: logical memory showed aGHQ APOE e4 al-
lele interaction effect (p = .04) and there was a (positive)
main effect of APOE e4 on vocabulary. In APOE e4 car-
riers, the correlation between GHQ and logical memory
was −0.07 versus −0.03 in APOE e4 noncarriers. In the
60- to 94-year-old group analysis of APOE genotypes, anJune 2015
 Unauthorized reproduction of this article is prohibited.
TABLE 2. Mean (Standard Deviation) Values/Frequencies for the Predictor and Outcome Variables, Shown
Separately for Groups Aged 18–59 and 60–94 Years
Adults Aged 18–59 y (n = 14,379) Adults Aged 60–94 y (n = 3944)
Predictor variables
Age, y 41.57 (11.97) 65.78 (5.74)
Sex, female 8456 (58.8%) 2248 (57%)
Current depression, yes 406 (2.8%) 49 (1.26%)
Lifetime depression, yes 1715 (11.93%) 380 (10.66%)
General Health Questionnairea 2.51 (4.09) 1.71 (3.3)
APOE e4 +e4: 4029 (28.02%) +e4: 1061 (36.8%)
APOE genotype
e2e2 92 (0.64%) 20 (0.51%)
e2e3 1668 (11.6%) 500 (12.68%)
e3e3 8590 (59.74%) 2363 (59.91%)
e2e4 311 (2.16%) 101 (2.56%)
e3e4 3353 (23.32%) 870 (22.06%)
e4e4 365 (2.54%) 90 (2.28%)
BMI, kg/m2 26.40 (5.27) 27.44 (4.88)
Chronic health conditions (range, 0–6) 0.31 (0.61) 0.82 (0.98)
Smoking status
Current 2757 411
Ex (<12 mo) 497 56
Ex (>12 mo) 3208 1619
Never 7917 1858
Alcohol, units/wk 10.71 (12.98) 18.94 (10.84)
Physical activity, d/wk
0 4970 1897
1 2147 461
2–3 4236 871
≥4 3026 715
Cognitive outcome measures
Digit Symbol 76.43 (15.62) 60.62 (15.07)
Verbal Fluency 39.93 (11.45) 40.66 (12.20)
Mill Hill Vocabulary 29.79 (4.45) 31.96 (4.67)
Logical Memory Total 31.81 (7.71) 29.10 (8.19)
APOE = apolipoprotein E; BMI = body mass index.
an = 14,279 in younger adults; n = 3913 in older adults.
ORIGINAL ARTICLEinteraction effect (not tested for current depression) be-
tween GHQ and APOE e4e4 was found for digit symbol
(p = .04). In APOE e4 homozygotes, there was no associa-
tion between GHQ and digit symbol compared with a sig-
nificant correlation of −0.18 in the APOE e3 homozygote
reference group. Given the number of multiple tests per-
formed, albeit on correlated dependent (cognitive) and in-
dependent (depression measure, APOE status, and
genotype) variables in two groups, the interaction effects,
all with p values greater than 0.04, are unlikely to represent
true effects, especially for the small APOE e4e4 genotypic
group in the 60- to 94-year-old sample.Psychosomatic Medicine, V 77 • 480-492 484
Copyright © 2015 by the American Psychosomatic Society.For the current and lifetime depression analyses, the ex-
clusion of bipolar cases changed two results in the geno-
typic analysis (although the direction of the effect did not
change), the main effect of current depression became sig-
nificant for vocabulary (p = .03) in the 18- to 59-year-old
group, and the main effect of lifetime depression became
nonsignificant for vocabulary (p = .051) in the 60- to
94-year-old group. However, the more reliable APOE e4
status analysis did not support a difference between these
analyses. For the GHQ analysis, the interaction effect of
GHQ and APOE e4 status for memory in the 18- to
59-year-old sample became nonsignificant (p = .06) onJune 2015
 Unauthorized reproduction of this article is prohibited.
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GHQ  APOE e3e4 interaction effect became significant
(p = .04) such that the correlation between GHQ and digit
symbol was larger in the APOE e3e4 group (−0.08) com-
pared with the APOE e3 homozygote reference group
(−0.05). All other effects were unchanged.DISCUSSION
The present study found no strong evidence to support a
synergistic effect of depression or psychological distress
symptoms and APOE on four diverse cognitive domains
measured in adults aged 18 to 59 years and 60 to
94 years. The comparison of current versus lifetime depres-
sion main effects on cognitive performance revealed differ-
ences across varying cognitive tasks, with only digit
symbol showing a consistent main decrement effect across
current and lifetime depression states in the 18- to 59-year-
old sample. Themain effects of APOE are the same as those
reported in this sample by Marioni and colleagues (23) de-
spite using a slightly different age group split and set of
confounding covariates. Our main findings held on exclud-
ing cases with bipolar disorder.
The first important finding to emerge from our analysis
was the absence of an association between APOE e4 varia-
tion and depression. Some previous studies focusing on el-
derly cohorts have reported a higher frequency of APOE e4
alleles in those with depression (33–35). However, these
studies have been limited particularly by their small sample
size. For example, Rigaud et al. (34) reported an association
between APOE e4 status and late-life (but not early-life) de-
pression in a late-life depressed sample of only 23 partici-
pants. In addition, depression screening questionnaires
rather than clinical instruments have been used (e.g., Ref.
(35)). Other studies report an absence of an association
(e.g., Refs. 36–38), but these, too, have used very small co-
horts (e.g., n = 22 depressed participants). In the largest pre-
vious study, Rajan et al. (8) did not find an association
between APOE e4 status and depressive symptoms in a
sample 65 years and older (n = 4150). Our study of adults
aged 60 to 94 years uses a comparable sample size and rep-
licates this null association using depression diagnoses
rather than symptoms; furthermore, we confirm this null as-
sociation in the largest sample to date to test this association
in younger adults. The most reliable evidence, then, sug-
gests that APOE does not directly affect depressive symp-
toms or clinical states.
Second, we found that digit symbol was the only test af-
fected by both current and lifetime occurrence of depression
(in the 18- to 59-year-old group), with performance poorer
in depressed adults. Currently depressed older adults also
showed worse digit symbol scores than did nondepressed
older adults. Psychomotor slowing has been argued to
be a defining feature of melancholia (39), so currently,June 2015
 Unauthorized reproduction of this article is prohibited.
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ORIGINAL ARTICLEdepressed individuals would be expected to show worse
performance on digit symbol. However, the finding in the
younger group that those with lifetime depression also
show deficits indicates that the biological pathway underly-
ing depression might be constantly impaired. The source of
this impairment might stem from differences in brain struc-
ture or plasticity of depressed individuals (40,41) or might
represent a stable trait, like neuroticism, that is associated
withmood states, but does not moderate the relationship be-
tween depression and perceptual speed in the elderly (42).
The strong genetic correlation between digit symbol perfor-
mance with both bipolar (43) and major depressive (L. Hall,
personal communication) disorders further supports a more
enduring biological basis underlying their covariation. The
absence of a lifetime occurrence of depression main effect
on digit symbol in the 60- to 94-year-old group suggests
that this lasting relationship might break down during
the aging process. Alternatively, the older aged sample
could be underpowered to detect such effects if they are
weaker for individuals in a euthymic versus currently de-
pressed phase.
The only other cognitive test negatively associated with
depression (current only) was logical memory in the 18- to
59-year-old group. In the 60- to 94-year-old group, this ef-
fect was of the same magnitude and, with a larger sample,
may have reached significance. Lifetime depression con-
ferred positive effects on verbal fluency and vocabulary
(both significant in the younger group and vocabulary sig-
nificant in the older group). Meta-analysis has shown en-
hanced verbal compared with performance IQ in people
with affective disorders (44), with a small number of studies
documenting superior verbal abilities in depressed individ-
uals compared with controls (45,46).More recent and much
larger studies show a relationship between very high gen-
eral intelligence and bipolar disorder (47), although results
for unipolar depression are mixed (48,49). Unlike ours,
these latter studies did not separate verbal and performance
abilities, and this may account for discrepancies in their
findings if the general cognitive ability measure is differen-
tially biased toward either verbal or performance subtests.
The negative associations between depression and verbal
abilities (e.g., Ref. (12)) previously reported are for mea-
sures of current depression, which align with our, albeit
nonsignificant, results for current depression and GHQ.
With regard to APOE main effects, these have been re-
ported previously in this sample (23). Briefly, we confirm
Wisdom and colleagues' (3) meta-analysis result that APOE
e4 allele carriers (particularly e4 homozygotes) have worse
performance on episodic memory and perceptual speed
tasks, but only in adults aged 60 to 94 years. Vocabulary
is a cognitive domain typically spared by the aging pro-
cess (50), and accordingly, we found no APOE effects
for this trait. Surprisingly, carriers of the APOE e3e4
genotype in the 18- to 59-year-old group and carriersPsychosomatic Medicine, V 77 • 480-492 490
Copyright © 2015 by the American Psychosomatic Society.of the e4e4 genotype in the 60- to 94-year-old group
demonstrated superior performance on verbal fluency.
In the GS:SFHS, verbal fluency scores, like vocabulary
scores, are quite resilient to aging effects (23), so it might
be that these abilities involve biological pathways that
are spared from APOE's negative effects. Moreover, def-
icits to memory and speed caused by APOE might force
individuals to compensate by drawing on alternative neu-
ral resources that consequently improves their main asso-
ciated functions.
Depression did not interact with APOE to affect cogni-
tive performance, and the interactions identified for current
psychological distress (a more powerful analysis which can
be considered a proxy for current depression) were likely to
represent Type 1 error given their marginal significance
level uncorrected for multiple testing. Because such an ef-
fect has been demonstrated for cognitive decline (7,8) in
studies sufficiently powered to compare APOE e4 presence
versus absence, one must ask why the interaction exists for
cognitive decline but not for stable cognitive ability. Al-
though childhood IQ predicts a large amount of variance
in IQmeasured later in life (~50%) (51), it explains substan-
tially less in cognitive change as people age. For instance,
Gow et al. (52) estimated that age 11 IQ predicted only
1.4% of variance in cognitive change between the years
of 79 and 83. A similar estimate was found in a larger co-
hort for memory and speed decline between the years of
43 and 53 (53). Given the high statistical power of our
study, particularly for the lifetime depression and APOE
e4 status analysis, our results then suggest that this syner-
gistic effect of depression and APOE only operates on cog-
nitive decline and not on stable cognition. In seeking an
explanation for the cause of this interaction effect, one must
focus then on those biological processes that are especially
susceptible to change with aging; these might include the
development of white matter hyperintensities (54), atrophy
of the brain and other neural changes (55), changing levels
of soluble and insoluble amyloid-β peptides (56), and
changes in immune activity and inflammatory responses
(57). These pathways have been implicated in both depres-
sion and APOE/AD studies (58–60).
In summary, our study of an ethnically homogeneous
population (99% of the depressed participants were
self-reported white) found a) no association between de-
pression diagnosis and APOE variation; b) differences
between current depression and lifetime depression ef-
fects on cognitive abilities, including positive effects on
verbal tests for lifetime depression; and c) no depression
by APOE interaction effect on cognitive ability, suggest-
ing that this effect is only relevant to cognitive decline (as
shown by others) and not the predominantly stable cogni-
tive abilities, which we were limited to measure here.
Longitudinal assessments of this cohort are needed to es-
tablish this possibility.June 2015
 Unauthorized reproduction of this article is prohibited.
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